LONDON, Jan. 18, 2022 /PRNewswire/ — Dragonfly Biosciences Limited, the makers of Dragonfly CBD, Europe’s largest and leading, seed to shelf range of CBD oils and skincare products, are advancing a strategy to become a global leader in delivering wellness at pace. Building upon its market leadership across the UK, Dragonfly moved to an initial public offering on the Australian Stock Exchange last month (December 2021). Public ownership was just one strategic element establishing an Australian beach-head at the centre of an Indo-Pacific market offensive to capture key growth economies. To deliver robust market penetration throughout the USA, Thought Leaders Inc., have been engaged under a Heads of Agreement, comprehensively geared towards meeting high-performance targets across all US market sectors.
Thought Leaders, a US health, wellness and IP Research & Development and investment company, announced today that they have secured an exclusive US Master license for Dragonfly Biosciences, one of the world’s most respected CBD Brands.
Thought Leaders’ plans to launch in mid 2022 Dragonfly premium CBD infused wellness products in the US, the world’s largest market for CBD infused wellness products. Thought Leaders is planning an extensive, game-changing direct-to-consumer sales programme along with conventional retail distribution in select…